Unicycive Therapeutics, Inc. (UNCY)
- Previous Close
0.4101 - Open
0.4120 - Bid 0.4133 x 300
- Ask 0.4240 x 100
- Day's Range
0.3938 - 0.4277 - 52 Week Range
0.2020 - 1.8180 - Volume
732,344 - Avg. Volume
2,461,787 - Market Cap (intraday)
39.998M - Beta (5Y Monthly) 2.33
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.08
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
unicycive.comRecent News: UNCY
View MorePerformance Overview: UNCY
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: UNCY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: UNCY
View MoreValuation Measures
Market Cap
38.70M
Enterprise Value
43.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
39.26
Price/Book (mrq)
--
Enterprise Value/Revenue
47.00
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-53.37%
Return on Equity (ttm)
-121.76%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-24.41M
Diluted EPS (ttm)
-0.3600
Balance Sheet and Cash Flow
Total Cash (mrq)
41.78M
Total Debt/Equity (mrq)
2.02%
Levered Free Cash Flow (ttm)
-16.69M